Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy

Author(s): Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, et al.

Abstract

Adult stem cells from human bone marrow stroma, referred to as mesenchymal stem cells or marrow stromal cells (hMSCs), are attractive candidates for clinical use. The optimal conditions for hMSC expansion require medium supplemented with fetal calf serum (FCS). Some forms of cell therapy will involve multiple doses, raising a concern over immunological reactions caused by medium-derived FCS proteins. By a sensitive fluorescence-based assay we determined that 7 to 30 mg of FCS proteins are associated with a standard preparation of 100 million hMSCs, a dosage that probably will be needed for clinical therapies. Here we present ex vivo growth conditions for hMSCs that reduce the FCS proteins to less than 100 ng per 100 million hMSCs, approximately a 100,000-fold reduction. The cells maintain their proliferative capacity and sustain their ability for multilineage differentiation. Experiments in rats demonstrate that rat MSCs grown in 20% FCS induce a substantial humoral response after repeated administrations, whereas cells grown under the conditions described in this study reduce the immunogenicity in terms of IgG response over 1000-fold to barely detectable levels. Our results have the potential to dramatically improve cellular and genetic therapies using hMSCs and perhaps other cells.

Similar Articles

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

Author(s): Riordan NH, Ichim TE, Min WP, Wang H, Solano F, et al.

Isolation and characterization of multi-potent stem cells from human orbital fat tissues

Author(s): Ho JH, Ma WH, Tseng TC, Chen YF, Chen MH, et al.

Isolation and characterization of canine adipose-derived mesenchymal stem cells

Author(s): Neupane M, Chang CC, Kiupel M,Yuzbasiyan-Gurkan V

Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives

Author(s): Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, et al.

Progenitor-enriched adipose tissue transplantation as rescue for breast implant complications

Author(s): Yoshimura K, Asano Y, Aoi N, Kurita M, Oshima Y, et al.

Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report

Author(s): Lendeckel S, Jodicke A, Christophis P, Heidinger K, Wolff J, et al.

Adipose-derived stromal cells: Their identity and uses in clinical trials, an update

Author(s): Casteilla L, Planat-Benard V, Laharrague P,Cousin B

A simple modification of the separation method reduces heterogeneity of adipose-derived stem cells

Author(s): Griesche N, Luttmann W, Luttmann A, Stammermann T, Geiger H, et al.

Characterization of adipose tissue-derived cells isolated with the Celution system

Author(s): Lin K, Matsubara Y, Masuda Y, Togashi K, Ohno T, et al.

Sera of overweight people promote in vitro adipocyte differentiation of bone marrow stromal cells

Author(s): Di Bernardo G, Messina G, Capasso S, Del Gaudio S, Cipollaro M, et al.

Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy

Author(s): Perez-Ilzarbe M, Diez-Campelo M, Aranda P, Tabera S, Lopez T, et al.

Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media

Author(s): Valencic E, Loganes C, Cesana S, Piscianz E, Gaipa G, et al.

Ex vivo expansion of human mesenchymal stem cells in defined serum-free media

Author(s): Jung S, Panchalingam KM, Rosenberg L,Behie LA

Optimizing proliferation and characterization of multipotent stem cells from porcine adipose tissue

Author(s): Wang KH, Kao AP, Wangchen H, Wang FY, Chang CH, et al.

Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke

Author(s): Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, et al.

Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial

Author(s): Badet L, Benhamou PY, Wojtusciszyn A, Baertschiger R, Milliat-Guittard L, et al.

Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries

Author(s): De Francesco F, Tirino V, Desiderio V, Ferraro G, D'Andrea F, et al.